ALK-Abello A/S 2018 AR2
The report outlines ALK's financial and strategic progress in 2018, marking the first year of its three-year business transformation. The company achieved total revenue of DKK 2.9 billion, driven by a 28% growth in SLIT-tablet sales, particularly in Europe and Japan. ALK successfully launched its ODACTRA tablet in the USA and ACARIZAX in France, while also expanding its digital patient engagement platforms like klarify.me. Despite strategic investments leading to a net loss of DKK 170 million, the company improved its manufacturing robustness and rationalized its product portfolio to support long-term growth.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2018
Type: AR2
Pages: 94
Back to company
ALK-Abello A/S
Annual Report
The report outlines ALK's financial and strategic progress in 2018, marking the first year of its three-year business transformation. The company achieved total revenue of DKK 2.9 billion, driven by a 28% growth in SLIT-tablet sales, particularly in Europe and Japan. ALK successfully launched its ODACTRA tablet in the USA and ACARIZAX in France, while also expanding its digital patient engagement platforms like klarify.me. Despite strategic investments leading to a net loss of DKK 170 million, the company improved its manufacturing robustness and rationalized its product portfolio to support long-term growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees